Boardroom Alpha
Boardroom Alpha
USPH · Current Report (Form 8-K) · Filed April 15, 2026

U S Physical Therapy Inc — Current Report (Form 8-K)

Form
8-K
Filed
April 15, 2026
Period
Apr 14, 2026
Ticker
USPH
Accession
0000885978-26-000017
Boardroom Alpha · Filing insights

U.S. Physical Therapy secured a new $450 million senior credit facility, refinancing debt and funding growth.

About U S Physical Therapy Inc
Market cap
$951M
1Y TSR
−14.8%
3Y TSR
−15.2%
Board grade
B-
Sector
Healthcare
CEO
Christopher J Reading
Last annual meeting: May 19, 2026 · View full U S Physical Therapy Inc profile →


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K


 CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 14, 2026


 U. S. PHYSICAL THERAPY, INC.
(Exact name of registrant as specified in its charter)


Nevada

 
001-11151

 
76-0364866

(State or other jurisdiction
of incorporation or organization)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)

1300 WEST SAM HOUSTON PARKWAY SOUTH,
SUITE 300, HOUSTON, Texas
 
77042

(Address of Principal Executive Offices)
 
(Zip Code)

Registrant's telephone number, including area code: (713) 297-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   

Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value USPH New York Stock Exchange
Common Stock, $.01 par value USPH NYSE Texas, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 
Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


  Item 1.01 Entry into a Material Definitive Agreement.
On April 14, 2026, U. S. Physical Therapy, Inc. (the “Company”), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, entered into the Fourth Amended and Restated Credit Agreement (the “Credit Agreement”) among Bank of America, N.A., as administrative agent (“Administrative Agent”) and the lenders from time-to-time party thereto.  The Credit Agreement syndicate consists of  BofA Securities, Inc. as Joint Lead Arranger and Sole Bookrunner, and Regions Capital Markets, a division of Regions Bank, as Joint Lead Arranger and Syndication Agent.  Other lenders include U.S. Bank National Association, JPMorgan Chase Bank, N.A. and Citizens Bank, N.A. as co-Documentation Agents and BankUnited, N.A. as participants.

The Credit Agreement, which matures on April 14, 2031, provides for loans in an aggregate principal amount of $450 million. Such loans will be available through the following facilities (collectively, the “Senior Credit Facilities”):

1)    Revolving Facility: $275 million, five-year, revolving credit facility (“Revolving Facility”), which includes a $25 million sublimit for the issuance of standby letters of credit and a $25 million sublimit for swingline loans (each, a “Swingline Loan”).

2)    Term Facility: $175 million term loan facility (the “Term Facility”). The Term Facility amortizes in quarterly installments of: (a) 0.625% in each of the first two years, (b) 1.25% in the third and fourth year, and (c) 1.875% in the fifth year of the Credit Agreement. The remaining outstanding principal balance of all term loans is due on the maturity date. 

The proceeds of the Revolving Facility shall be used by the Company for working capital and other general corporate purposes of the Company and its subsidiaries, including to fund future acquisitions and invest in growth opportunities. The proceeds of the Term Facility shall be used by the Company to refinance the indebtedness outstanding under the Third Amended and Restated Credit Agreement, to pay fees and expenses incurred in connection with the transactions contemplated hereby, for working capital and other general corporate purposes of the Company and its subsidiaries.

The Company will be permitted to increase the Revolving Facility and/or add one or more tranches of term loans in an aggregate amount not to exceed the sum of (i) $125 million plus (ii) an unlimited additional amount, provided that (in the case of clause (ii)), after giving effect to such increases, the pro forma Consolidated Leverage Ratio (as defined in the Credit Agreement) would not exceed 2.5:1.0.

The interest rates per annum applicable to the Senior Credit Facilities (other than in respect of Swingline Loans) will be Term SOFR (as defined in the Credit Agreement) plus an applicable margin or, at the option of the Company, an alternate base rate plus an applicable margin. Each Swingline Loan shall bear interest at the base rate plus the applicable margin. The applicable margin for Term SOFR borrowings ranges from 1.25% to 2.25%, and the applicable margin for alternate base rate borrowings ranges from 0.250% to 1.25%, in each case, based on the Consolidated Leverage Ratio of the Company and its subsidiaries. 

The Company may select interest periods of one, three or six months for Term SOFR borrowings. Interest is payable at the end of the selected interest period but no less frequently than quarterly and on the date of maturity.

The Company will also pay to the Administrative Agent, for the account of each lender under the Revolving Facility, a commitment fee equal to the actual daily excess of each lender’s commitment over its outstanding credit exposure under the Revolving Facility (“unused fee”). Such unused fee will range between 0.225% and 0.35% per annum and is also based on the Consolidated Leverage Ratio of the Company and its subsidiaries.  The Company may prepay and/or repay the revolving loans and the term loans, and/or terminate the revolving loan commitments, in whole or in part, at any time without premium or penalty, subject to certain conditions.

The Credit Agreement contains customary covenants limiting, among other things, the incurrence of additional indebtedness, the creation of liens, mergers, consolidations, liquidations and dissolutions, sales of assets, dividends and other payments in respect of equity interests, acquisitions, investments, loans and guarantees, subject, in each case, to customary exceptions, thresholds and baskets. The Credit Agreement includes certain financial covenants which include a consolidated fixed charge coverage ratio and a consolidated leverage ratio, as defined in the Credit Agreement. The Credit Agreement also contains customary events of default.
 
The Company’s obligations under the Credit Agreement are guaranteed by its material, wholly-owned,  domestic subsidiaries (each, a “Guarantor”), and the obligations of the Company and any Guarantors are secured by a perfected first priority security interest in substantially all of the existing and future personal property of the Company and each Guarantor, subject to certain exceptions. 

The Administrative Agent and other parties to the Credit Agreement have provided in the past, and may provide in the future, certain commercial banking, financial advisory, investment banking and other services for the Company and its affiliates in the ordinary course of their business, for which they have received and may continue to receive customary compensation and expense reimbursement.

On April 15, 2026, the Company issued a press release announcing its entry into the Credit Agreement. A copy of that press release is attached as Exhibit 99.1 hereto.

The description of the Credit Agreement set forth above is qualified in its entirety by reference to the Credit Agreement filed as exhibit 10.1 hereto and incorporated herein by reference.

Item 2.03    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

See Item 1.01 above.




ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS

     
Exhibits
 
Description of Exhibit
   
 
 Fourth Amended and Restated Credit Agreement dated as of April 14, 2026 among the Company, as the borrower, and Bank of America, N.A., as Administrative Agent, Regions Capital Markets, as Syndication Agent, Citizens Bank, N.A., JPMorgan Chase Bank, N.A., and U.S. Bank National Association, as Co-Documentation Agents, BofA Securities, Inc. and Regions Capital Markets, as Joint Lead Arrangers, BofA Securities, Inc., as Sole Bookrunner, and the lenders named therein. (Schedules pursuant to the Credit Agreement have not been filed by the Registrant, who hereby undertakes to file such schedules upon the request of the Commission.) *

99.1  
 Press release dated April 15, 2026, announcing a new credit facility.

Furnished herewith.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

               
       
U.S. PHYSICAL THERAPY, INC.
 
         
Dated: April 15, 2026
     
By:
 
/s/ CAREY HENDRICKSON
 
           
Carey Hendrickson
 
           
Chief Financial Officer
 
           
(duly authorized officer and principal financial and accounting officer)
 



From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from U S Physical Therapy Inc (USPH)

Reference

Frequently asked questions

When did U S Physical Therapy Inc file this 8-K?
U S Physical Therapy Inc (USPH) filed this Current Report (Form 8-K) with the SEC on April 15, 2026. The accession number assigned by EDGAR is 0000885978-26-000017.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
U.S. Physical Therapy secured a new $450 million senior credit facility, refinancing debt and funding growth. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find U S Physical Therapy Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K U S Physical Therapy Inc has filed under CIK 885978, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer